ERBB2 and osteosarcoma: Given the elevated risk for patients with overexpressed HER-2, it is natural to postulate that trastuzumab was effective in extending survival for these patients.[32] However, definitive evaluation of the treatment effect of trastuzumab for osteosarcoma requires randomized controlled trials of HER-2-positive patients.